Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer
Rhea-AI Summary
Can-Fite (NYSE American: CANF) announced that the Australian Patent Office has allowed Patent Application No. 2021290439, entitled “Treatment of Advanced Metastatic Cancer,” supporting the development and future marketing of its drug candidate Namodenoson in liver and pancreatic cancers.
Namodenoson is in a pivotal Phase 3 study for advanced hepatocellular carcinoma, following FDA and EMA protocol agreement. According to Can-Fite, a Phase 2a pancreatic cancer study showed an excellent safety profile, encouraging survival and durable disease stabilization, with a Phase 2b trial planned in combination with gemcitabine. The drug selectively targets the A3 adenosine receptor to induce tumor cell apoptosis while sparing normal tissue.
Positive
- Australian patent allowance for Patent Application No. 2021290439 on treatment of advanced metastatic cancer
- Namodenoson in pivotal Phase 3 trial for advanced hepatocellular carcinoma with FDA and EMA protocol agreement
- Phase 2a pancreatic cancer study completed; company reports excellent safety, encouraging survival, and durable disease stabilization with Phase 2b planned
Negative
- None.
News Market Reaction – CANF
In the Jul 14 session, CANF declined 1.23%, reflecting a mild negative market reaction. Argus tracked a peak move of +13.5% during that session. Argus tracked a trough of -8.9% from its starting point during tracking. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 06 | Phase 3 psoriasis milestone | Positive | -2.8% | Completion of enrolment for interim analysis in pivotal Phase 3 psoriasis trial. |
| Jul 01 | Phase 2a pancreatic data | Positive | +55.9% | Phase 2a pancreatic study met safety endpoint with durable survival in advanced disease. |
| Jun 26 | Japanese patent allowance | Positive | -6.5% | Japan patent allowance for Namodenoson’s anti-obesity technology expanding IP estate. |
| Jun 22 | Peer-reviewed A3AR article | Positive | +6.7% | Publication reviewing broad therapeutic potential of Piclidenoson and Namodenoson. |
| Jun 17 | BIO convention presentation | Positive | +1.0% | Planned presentations and partnering meetings on late-stage pipeline and licensing. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has been consistently positive, but price responses are mixed, with three of five events showing moves aligned with the constructive clinical or IP catalysts.
Key Terms
phase 3 medical
phase 2a medical
phase 2b medical
hepatocellular carcinoma medical
gemcitabine medical
apoptosis medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Ramat Gan, Israel, July 14, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that the Australian Patent Office has allowed Patent Application No. 2021290439 entitled "Treatment of Advanced Metastatic Cancer."
The patent complements Can-Fite's rapidly advancing oncology pipeline. Namodenoson is currently being evaluated in a pivotal Phase 3 study for advanced hepatocellular carcinoma following FDA and EMA protocol agreement. In pancreatic cancer, the Company recently completed a Phase 2a clinical study demonstrating an excellent safety profile together with encouraging survival outcomes and durable disease stabilization and is planning a Phase 2b study evaluating Namodenoson in combination with gemcitabine.
"This patent allowance further strengthens our global intellectual property portfolio surrounding Namodenoson and reinforces the long-term value of our oncology franchise," said Pnina Fishman, Ph.D., Chairperson and Chief Scientific Officer of Can-Fite BioPharma. "Importantly, the patent supports two of our most advanced oncology programs—hepatocellular carcinoma and pancreatic cancer—and extends protection for our innovative therapeutic approach in a major international market."
Namodenoson selectively targets the A3 adenosine receptor (A3AR), which is highly expressed in inflammatory and cancer cells. Activation of A3AR has been shown to induce apoptosis of tumor cells while sparing normal tissues, contributing to the compound's favorable safety profile demonstrated across clinical studies.
About Namodenoson
Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR). Namodenoson is currently being evaluated in a pivotal Phase 3 trial for advanced liver cancer, concluded successfully a Phase 2a study in pancreatic cancer and enroll patients for a Phase 2b trial for the treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH). A3AR is highly expressed in diseased cells whereas low expression is found in normal cells. This differential expression may be one of the important factors that accounts for the excellent safety of the drug.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company’s lead drug candidate, Piclidenoson recently reported topline results in a Phase 3 trial for psoriasis and commenced a pivotal Phase 3 trial. Can-Fite’s liver drug, Namodenoson, is being evaluated in a Phase III trial for hepatocellular carcinoma (HCC), a Phase 2b trial for the treatment of MASH, and in a Phase 2a study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company’s third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date. For more information please visit: www.canfite.com.
Forward-Looking Statements
This press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, the Company’s plans to conduct a Phase 2b study evaluating Namodenoson in combination with gemcitabine. All statements in this communication, other than those relating to historical facts, are “forward looking statements”. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our market and other conditions, history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to not satisfying the continued listing requirements of NYSE American; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the “Risk Factors” section of Can-Fite’s Annual Report on Form 20-F filed with the SEC on March 26, 2026 and other public reports filed with the SEC and in its periodic filings with the TASE. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Can-Fite undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.
Contact
Can-Fite BioPharma
Motti Farbstein
info@canfite.com
+972-3-9241114
